6 Result(s) found
Current Studies
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer -
Part A Primary To compare the efficacy of olomorasib in combination with pembrolizumab versus placebo with pembrolizumab Secondary To compare olomorasib in combination with pembrolizumab versus placebo with pembrolizumab for the following measures: efficacy, changes in HRQoL, safety,...
View DetailsCurrent Studies
Proximal FEmur Reconstruction or Internal Fixation fOR Metastases Randomized Controlled Trial PERFORM
The overall objective of the PERFORM trial is to determine the effect of resection and reconstruction on patient-important outcomes compared to internal fixation for the stabilization of an impending or realized pathologic fracture in patients with metastatic bone disease of the proximal femur. We...
View DetailsCurrent Studies
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab...
View DetailsCurrent Studies
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Previously Treated Extensive Stage Small Cell Lung Cancer (ESSCLC)
Primary Objectives To compare the effect of SG to SOC on ORR as assessed by BICR according to the RECIST v1.1 To compare the effect of SG to SOC on OS Secondary Objectives To compare the effect of SG to SOC on PFS as assessed by BICR according to RECIST v1.1 To compare the effect of SG to SOC on...
View DetailsCurrent Studies
A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Ce
To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS by BICR in all randomised participants.
View DetailsCurrent Studies
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression &#
Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE) Part A and Part B: Progression-Free Survival (PFS)
View Details